pp-046 Solution for infusion
Dossier type
CTD
Dossier status
Under development
Country of origin
South Korea
Comments
Indication: Cancer cachexia and other chronic disease–associated cachexia syndromes (wasting conditions with severe loss of muscle and body weight).
Clinical stage: Preclinical (U.S.-based program).
Modality: Biologic (monoclonal antibody).
Mechanism / Target: Anti-GDF15 IgG1 monoclonal antibody, designed to neutralize GDF15 — a key circulating factor implicated in appetite suppression, weight loss, and metabolic dysregulation in cachexia.
Route / form: Intravenous monoclonal antibody therapy (projected).
Differentiation: One of the few biologic agents directly targeting the GDF15 pathway, a central regulator of cachexia; potential first-in-class therapeutic approach.
Manufacturer #16907
This South Korea–based life-sciences organization develops a portfolio of small-molecule and biologic therapeutics, with a strategic focus on oncology, immunology, and metabolic diseases. Its pharmaceutical R&D is supported by global clinical programs and collaborations aimed at advancing first-in-class and best-in-class candidates. The group also maintains established therapeutic franchises and leverages international partnerships to expand its presence in the global healthcare market.
Manufacturer usually replies in 53 days